Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

A. Tsuji; M. Nakamura; T. Watanabe; D. Manaka; H. Matsuoka; M. Kataoka; M. Takeuchi; W. Ichikawa; M. Fujii

doi:10.1093/annonc/mdy151.242

Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

A. Tsuji
, M. Nakamura
, T. Watanabe
, D. Manaka
, H. Matsuoka
, M. Kataoka
, M. Takeuchi
, W. Ichikawa
, M. Fujii

Gastrointestinal Surgery

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	v68-v69
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy151.242
Publication status	Published - 01-06-2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Hematology
Oncology

Access to Document

10.1093/annonc/mdy151.242

Cite this

Tsuji, A., Nakamura, M., Watanabe, T., Manaka, D., Matsuoka, H., Kataoka, M., Takeuchi, M., Ichikawa, W., & Fujii, M. (2018). Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v68-v69. https://doi.org/10.1093/annonc/mdy151.242

@article{3dc416c0605e4d6294f02073c7770ae9,

title = "Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy",

author = "A. Tsuji and M. Nakamura and T. Watanabe and D. Manaka and H. Matsuoka and M. Kataoka and M. Takeuchi and W. Ichikawa and M. Fujii",

year = "2018",

month = jun,

day = "1",

doi = "10.1093/annonc/mdy151.242",

language = "English",

volume = "29",

pages = "v68--v69",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

}

Tsuji, A, Nakamura, M, Watanabe, T, Manaka, D, Matsuoka, H, Kataoka, M, Takeuchi, M, Ichikawa, W & Fujii, M 2018, 'Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. v68-v69. https://doi.org/10.1093/annonc/mdy151.242

Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. / Tsuji, A.; Nakamura, M.; Watanabe, T. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.06.2018, p. v68-v69.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

AU - Tsuji, A.

AU - Nakamura, M.

AU - Watanabe, T.

AU - Manaka, D.

AU - Matsuoka, H.

AU - Kataoka, M.

AU - Takeuchi, M.

AU - Ichikawa, W.

AU - Fujii, M.

PY - 2018/6/1

Y1 - 2018/6/1

UR - https://www.scopus.com/pages/publications/85059484778

UR - http://www.scopus.com/inward/citedby.url?scp=85059484778&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy151.242

DO - 10.1093/annonc/mdy151.242

M3 - Article

C2 - 32177225

SN - 0923-7534

VL - 29

SP - v68-v69

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M et al. Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29:v68-v69. doi: 10.1093/annonc/mdy151.242

Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this